Analyst Reco. Eli Lilly and Company

Equities

LLY

US5324571083

Pharmaceuticals

Market Closed - Nyse Other stock markets 21:00:02 12/12/2025 GMT			5-day change	1st Jan Change
1,027.51 ^USD	+1.80%		+1.70%	+33.10%

12-12	Health Care Flat on Defensive Bias - Health Care Roundup	DJ
12-12	Sector Update: Health Care Stocks Advance Late Afternoon	MT

Analyst Reco.

Analyst recommendations: Lululemon, Snap, Broadcom, Roblox, SanDisk…	12-12
Roche Kept at Buy as BofA Notes 'Positive' Late-stage Pipeline Data	12-11	MT
Wells Fargo Adjusts PT on Eli Lilly and Company to $1,200 From $1,100, Maintains Overweight Rating	12-10	MT
HSBC Adjusts PT on Eli Lilly and Company to $1,070 From $850, Maintains Hold Rating	12-10	MT
Analyst recommendations: Abbvie, Biogen, PepsiCo, Eli Lilly, Netflix…	12-10
Goldman Sachs Adjusts Price Target on Eli Lilly and Co. to $1,145 From $951, Maintains Buy Rating	12-08	MT
BMO Capital Adjusts PT on Eli Lilly and Company to $1,200 From $1,100, Maintains Outperform Rating	12-04	MT
Wolfe Research Adjusts PT on Eli Lilly and Company to $1,250 From $1,050, Maintains Outperform Rating	12-03	MT
Guggenheim Adjusts Price Target on Eli Lilly and Company to $1,163 From $1,036, Maintains Buy Rating	12-03	MT
Eli Lilly Price Target, Earnings Estimates Up as Berenberg Highlights Strong Q3, Upcoming Catalysts	12-02	MT
Berenberg Adjusts Price Target on Eli Lilly and Co. to $950 From $830, Maintains Hold Rating	12-02	MT
AlphaValue/Baader Europe Notes 'Extremely Adverse' Investor Sentiment on Novo Nordisk; Price Target Down	11-25	MT
Sector Update: Health Care Stocks Advance Late Afternoon	11-24	MT
Sector Update: Health Care Stocks Advance in Afternoon Trading	11-24	MT
Sector Update: Health Care	11-24	MT
Eli Lilly Benefits From 'Broadening' GLP-1 Market, Morgan Stanley Says	11-24	MT
Bernstein Adjusts PT on Eli Lilly and Co. to $1,300 From $1,100, Maintains Outperform Rating	11-24	MT
Morgan Stanley Adjusts PT on Eli Lilly and Co. to $1,290 From $1,171, Maintains Overweight Rating	11-24	MT
Truist Raises Price Target on Eli Lilly to $1,182 From $1,038, Keeps Buy Rating	11-19	MT
Truist Raises Price Target on Eli Lilly to $1,182 From $$1,038, Keeps Buy Rating	11-19	MT
JPMorgan Adjusts PT on Eli Lilly and Co. to $1,150 From $1,050, Maintains Overweight Rating	11-18	MT
Scotiabank Initiates Eli Lilly and Co. at Sector Outperform With $1,165 Price Target	11-13	MT
Morgan Stanley Adjusts PT on Eli Lilly and Co. to $1,171 From $1,090, Maintains Overweight Rating	11-13	MT
CICC Adjusts Price Target on Eli Lilly and Co. to $1,060 From $801, Maintains Neutral Rating	11-13	MT
Analyst recommendations: AMD, Dollar Tree, Comcast, Nike, Cisco…	11-13

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Lilly Cuts Prices for Cash Buyers of Weight-Loss Drug Zepbound

December 01, 2025 at 03:39 pm

Is it back to square one for Eli Lilly?

August 07, 2025 at 04:20 pm